Axovant Sciences Ltd. (NYSE:AXON) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $15.00 target price on the stock. Zacks Investment Research’s target price would suggest a potential upside of 14.24% from the company’s current price.

According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “

A number of other brokerages have also recently weighed in on AXON. Piper Jaffray Cos. set a $32.00 price objective on shares of Axovant Sciences and gave the company a “buy” rating in a report on Friday, September 23rd. Evercore ISI restated a “buy” rating and issued a $29.00 price objective on shares of Axovant Sciences in a report on Friday, September 23rd. Jefferies Group restated a “buy” rating and issued a $31.00 price objective on shares of Axovant Sciences in a report on Monday, September 26th. Leerink Swann restated a “buy” rating on shares of Axovant Sciences in a report on Thursday, June 30th. Finally, Robert W. Baird restated an “outperform” rating and issued a $29.00 price objective on shares of Axovant Sciences in a report on Friday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.33.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Axovant Sciences (NYSE:AXON) traded up 1.16% on Tuesday, hitting $13.13. 170,605 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $15.10 and its 200-day moving average price is $13.73. The company’s market cap is $1.30 billion. Axovant Sciences has a 12-month low of $8.86 and a 12-month high of $21.30.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.02. Analysts forecast that Axovant Sciences will post ($1.68) earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of AXON. BlackRock Inc. increased its stake in Axovant Sciences by 4.7% in the first quarter. BlackRock Inc. now owns 36,659 shares of the company’s stock valued at $421,000 after buying an additional 1,659 shares during the period. BlackRock Group LTD increased its stake in Axovant Sciences by 2.1% in the first quarter. BlackRock Group LTD now owns 148,704 shares of the company’s stock valued at $1,707,000 after buying an additional 3,126 shares during the period. Sabby Management LLC acquired a new stake in Axovant Sciences during the first quarter valued at approximately $391,000. Alps Advisors Inc. increased its stake in Axovant Sciences by 24.9% in the second quarter. Alps Advisors Inc. now owns 139,286 shares of the company’s stock valued at $1,788,000 after buying an additional 27,780 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Axovant Sciences by 39.3% in the second quarter. Bank of New York Mellon Corp now owns 72,198 shares of the company’s stock valued at $928,000 after buying an additional 20,368 shares during the period. Institutional investors and hedge funds own 29.45% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.